Enzyvant's Investigational Farber Disease Enzyme Replacement Therapy, RVT-801, Receives FDA Fast Track and Rare Pediatric Disease Designations

CAMBRIDGE, Mass. and BASEL, Switzerland, March 21, 2019 -- (Healthcare Sales & Marketing Network) -- Enzyvant, a biopharmaceutical company focused on developing and commercializing transformative therapies for patients with rare diseases, today announced ... Biopharmaceuticals, FDA Enzyvant, Roivant Sciences, Farber Disease, enzyme replacement therapy
Source: HSMN NewsFeed - Category: Pharmaceuticals Source Type: news